ENDPOINTS

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff

Plus, news about Immunic, Neurocrine Biosciences, Alcon, AusperBio and Evommune: Taysha Gene Therapies reveals plans for pivotal trial, $200M offering: The biotech on Wednesday disclosed design details for its pivotal Part ...

May 29, 2025 - 16:14
 0
Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff
Plus, news about Immunic, Neurocrine Biosciences, Alcon, AusperBio and Evommune: Taysha Gene Therapies reveals plans for pivotal trial, $200M offering: The biotech on Wednesday disclosed design details for its pivotal Part ...
Read More

Tags:

Previous Article

Skipping migration: City-dwelling monarch butterflies stay put

Next Article

Omada Health aims for $1.1B valuation with IPO

Related Posts

Vinay Prasad makes first major imprint on FDA with new vaccine policy

Vinay Prasad makes first major imprint on FDA with new ...

May 20, 2025  0

Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong

Moderna pulls application for Covid-flu shot; Another I...

May 21, 2025  0

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

FDA adcomm votes unanimously against Pfizer's prostate ...

May 22, 2025  0